

# Alpramil 5 mg/50 mg tablets for dogs weighing at least 0.5 kg

Authorised

- Praziquantel
- Milbemycin oxime

## Product identification

**Medicine name:**

Alpramil 5 mg/50 mg tablets for dogs weighing at least 0.5 kg

---

**Active substance:**

Praziquantel  
Milbemycin oxime

---

**Target species:**

Dog

---

**Route of administration:**

Oral use

---

## Product details

**Active substance and strength:**

Praziquantel  
50.00 milligram(s) / 1.00 Tablet  
Milbemycin oxime

5.00 milligram(s) / 1.00 Tablet

---

**Pharmaceutical form:**

Tablet

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QP54AB51

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Poland

---

**Package description:**

Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.  
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.  
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.  
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.  
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.  
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.  
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 4 tablets.  
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 2 tablets  
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 1 tablet.

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

---

**Marketing authorisation holder:**

Alfasan Nederland B.V.

---

**Marketing authorisation date:**

8/06/2022

---

**Manufacturing sites for batch release:**

Lelypharma B.V.

Alfasan Nederland B.V.

---

**Responsible authority:**

Office For Registration Of Medicinal Products Medical Devices And Biocidal Products

---

**Authorisation number:**

3191

---

**Date of authorisation status change:**

8/06/2022

---

**Reference member state:**

Netherlands

---

**Procedure number:**

NL/V/0364/004

---

**Concerned member states:**

Belgium Bulgaria Croatia Cyprus Czechia Estonia Finland France Germany  
Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway  
Poland Portugal Romania Slovakia Slovenia Spain

United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to  
[www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

Combined File of all Documents

## Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

## Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

## Labelling

This document does not exist in this language (English). You can find it in another language below.

NL\_V\_0364\_004-006\_DC Milpramax tablets for dogs-Final PuAR.pdf